Source-grounded facts extracted from TuHURA Biosciences, Inc./NV's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TuHURA Biosciences, Inc./NV incurred revolving credit of $1,700,000 with Parkview Holdings One LLC maturing April 21, 2031.
“On May 26, 2026, the Company received its first draw under the revolving credit facility for an amount of $1,700,000 and expects to use the funds for general corporate purposes.”
TuHURA Biosciences, Inc./NV incurred revolving credit of $50 million revolving credit facility with Parkview Holdings One LLC at 12% per annum (plus additional 6% during an event of default) maturing April 21, 2031.
“On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.”
TuHURA Biosciences, Inc./NV entered into Loan Agreement with Parkview Holdings One LLC valued at $50 million (effective 2026-04-21).
“On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.”
TuHURA Biosciences, Inc./NV reported financial results for for the Company's fourth quarter and full year ended December 31, 2025.
“TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update”
TuHURA Biosciences, Inc./NV reported financial results for for the year ended December 31, 2025.
“On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update.”
TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing R”
TuHURA Biosciences, Inc./NV amended loan with Matthew Nachtrab Revocable Trust dated 12/18/2014.
“(the “Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3.0 million (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement (the “Availability Period”).”
TuHURA Biosciences, Inc./NV incurred loan of $1.5 million with Matthew Nachtrab Revocable Trust dated 12/18/2014.
“the Company borrowed an additional $1.5 million from the Lender under the Loan Agreement (the “Second Loan”), which resulted in aggregate Loans of $3.0 million made to the Company under the Loan Agreement.”
TuHURA Biosciences, Inc./NV incurred loan of up to $3,000,000 with Matthew Nachtrab Revocable Trust dated 12/18/2014 at 3% per month maturing the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash.
“Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement.”
TuHURA Biosciences, Inc./NV completed an acquisition involving Kineta, Inc. for 0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock (closed 2025-06-30).
“share of Kineta common stock, par value $0.001 per share (each, a “Share”), issued and outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of TuHURA common stock, par value $0.001 per share (“TuHURA Common Stock”), for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock. Also pursuant to the”
TuHURA Biosciences, Inc./NV: Increased authorized shares of common stock from 75 million to 200 million (effective 2025-06-23).
“the stockholders of the Company approved an amendment to the Company's Articles of Incorporation increasing the number of authorized shares of common stock from 75 million to 200 million shares”
Dennis Yamashita was terminated as Chief Scientific Officer at TuHURA Biosciences, Inc./NV.
“the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024”
Craig Tendler was appointed as Director at TuHURA Biosciences, Inc./NV.
“On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
TuHURA Biosciences, Inc./NV engaged Cherry Bekaert LLP as its auditor.
“On December 27, 2024, following the completion of the Merger, the Audit Committee of the Company’s board of directors unanimously approved the appointment of Cherry Bekaert as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024.”
TuHURA Biosciences, Inc./NV dismissed Marcum LLP as its auditor.
“On December 31, 2024, as a result of completion of the Merger, Marcum was informed that it was dismissed as the Company’s independent registered public accounting firm.”
TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.
“As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.